Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts

Abstract Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on eosinophils. Both therapies reduce o...

Full description

Bibliographic Details
Main Authors: Arian Ghassemian, Jane Jiyoon Park, Michael W. Tsoulis, Harold Kim
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
Asthma
Biologics
Interlukin-5
Interlukin-5 receptor
Benralizumab
Mepolizumab
Online Access:https://doi.org/10.1186/s13223-020-00507-0

Similar Items

Similar Items